Posts by: Jose Marques Lopes, PhD

News

Treatment with Ocrevus (ocrelizumab) has superior or comparable effectiveness and a similar safety profile to other available disease-modifying treatments (DMTs) for treating relapsing multiple sclerosis (MS), ... Read more

January 17, 2019January 17, 2019

Fewer RRMS Patients Relapse, Discontinue Treatment with Gilenya, Study Finds

News

Relapsing-remitting multiple sclerosis (RRMS) patients on Gilenya (fingolimod) have fewer relapses and stay on treatment longer than those taking Tecfidera (dimethyl fumarate) or Aubagio (teriflunomide), according to ... Read more

January 15, 2019January 21, 2019

Ocrevus Targets Certain T-Cells, Along with B-Cells, in MS Patients, Study Reports

News

Treatment with a single dose of Ocrevus (ocrelizumab) depleted a subset of immune T-cells within two weeks in patients with relapsing multiple sclerosis (MS) or primary ... Read more

January 3, 2019January 8, 2019

Stem-like Th17 Cells May Lead to New Therapeutic Approaches for MS, Other Autoimmune Diseases, Study Suggests

News

An altered metabolism and signaling is associated with the ability of a subset of immune T helper 17 (Th17) cells to induce neuroinflammation, according to a ... Read more

January 2, 2019January 8, 2019

Pretreating Ocrevus Patients with Multiple Antihistamines and Liquids Lowers Infusion Reactions by 60%, Study Reports

News

Pretreating multiple sclerosis patients with antihistamines more extensively and with hydration can significantly reduce — by 60% — the likelihood of infusion-associated reactions that are the most common side effect ... Read more

December 7, 2018December 7, 2018

Aubagio Becomes 1st Once-daily Oral DMT for Relapsing MS Patients in India

News

Aubagio (teriflunomide) has become the first once-a-day, oral disease-modifying therapy (DMT) for multiple sclerosis (MS) to be approved for use in India. Sanofi Genzyme’s therapy is indicated for ... Read more

December 6, 2018December 6, 2018

Use of Hospital Palliative Care by MS Patients in US Rose 30-fold Between 2005-14, Study Finds

News

Palliative care in a hospital setting rose 30 fold among multiple sclerosis (MS) patients in the U.S. from 2005 to 2014, and was associated with longer hospital ... Read more

December 4, 2018December 13, 2018

RRMS Patients on Rebif Show High Treatment Adherence and Fewer Relapses in Real-World Study

News

Patients with relapsing-remitting multiple sclerosis (RRMS) on Rebif (interferon beta 1-a), using the RebiSmart autoinjector, have high treatment adherence, despite seasonal weather or temperature fluctuations, as well ... Read more

November 26, 2018December 4, 2018

Gilenya-induced Changes in Heart Rate May Predict Degree of Drop in Lymphocytes, Study Reports

News

Assessing changes in a person’s heart rate can help to predict the degree to which lymphocyte numbers will decrease in relapsing-remitting multiple sclerosis (RRMS) patients using Gilenya ... Read more

November 16, 2018November 16, 2018

Unemployment and Under-employment Linked to Poorer Cognitive Abilities in UK Study

News

Multiple sclerosis patients of working age who are unemployed or on a reduced work schedule are likely to show considerable cognitive impairment on tests, especially those measuring ... Read more

November 15, 2018November 26, 2018

Ocrevus Helps Preserve Hand and Arm Function in PPMS Patients, Trial Data Show

News

Treating primary progressive multiple sclerosis (PPMS) patients with Ocrevus (ocrelizumab) can help to preserve strength and function in their hands and the arms, analysis of data from ... Read more

November 12, 2018November 15, 2018

Controlling B-cell Numbers, Activity Key to Preventing Inflammation in MS, Study Suggests

News

Appropriate control of immune B-cell numbers and activation in the nervous system is key to preventing inflammation in multiple sclerosis (MS), according to a study. These ... Read more

November 7, 2018November 13, 2018

#ECTRIMS2018 – Better MS Monitoring and Disease Understanding Among Goals of FLOODLIGHT Open, Genentech Director Says

News

The ability to track multiple sclerosis (MS) at any time, gain a more complete picture of each patient’s disease course and a better understanding of MS ... Read more

November 6, 2018November 6, 2018

Denali and Sanofi Partner to Develop Potential Treatments for MS, Other Neurological Disorders

News

Denali Therapeutics and Sanofi will collaborate to develop a compound called DNL747 that may treat multiple sclerosis (MS) and other neurodegenerative disorders. The companies will also jointly work on the ... Read more

November 2, 2018November 8, 2018

Study Sheds New Light on Tecfidera’s Inhibitory Mechanism of Action

News

Multiple sclerosis (MS) treatment Tecfidera (dimethyl fumarate) binds to a specific amino acid in key enzymes to inhibit their activity, according to a study that sheds ... Read more

October 24, 2018October 30, 2018

#ECTRIMS2018 – Ocrevus Used Early in MS Course Key to Slowing Disability, Genentech Director Says

News

Treating patients with primary progressive or relapsing multiple sclerosis (MS) early with Ocrevus (ocrelizumab) is key to slowing disease progression, according to Hideki Garren, global head of ... Read more

October 23, 2018October 25, 2018

Changes in Temperature and Salt Affect Myelin and Raise Risk of MS, Study Says

News

Environmental changes, such as high temperatures and alterations in salt types and concentrations, trigger structural changes to myelin that may increase the risk of multiple sclerosis (MS), ... Read more

October 22, 2018October 30, 2018

#ECTRIMS2018 – Finding Best Treatment for ‘Right Patient’ and Progressive MS Among Work of Interest, Cleveland Clinic Doctors Say

News

Tailored, highly effective therapies early in the disease’s course may be a way forward in multiple sclerosis (MS) treatment, according to Cleveland Clinic neurologist Robert Bermel. Another ... Read more

October 18, 2018October 18, 2018

#ECTRIMS2018 – GNbAC1 Shows Consistent Neuroprotection in RRMS Patients, Phase 2b Study Reports

News

Treating relapsing-remitting multiple sclerosis (RRMS) patients with GeNeuro’s investigational compound GNbAC1 lessened brain atrophy and lesion load and suggested myelin preservation, according to results of a Phase ... Read more

October 17, 2018October 17, 2018

#ECTRIMS2018 – Serum Neurofilament Light Show Promise as Biomarker, But Not There Yet, Neurologists Say

News

Despite its lack of specificity to multiple sclerosis (MS) in particular, monitoring patients with a blood biomarker — serum neurofilament light (sNfL) — may hold promise ... Read more

October 17, 2018October 17, 2018

#ECTRIMS2018 – Blood Level of Neurofilament Light Chain May Predict Brain Atrophy in Progressive MS, Study Suggests

News

Measuring the blood level of neurofilament light chain (NfL) may predict brain shrinkage in primary progressive (PPMS) and secondary progressive multiple sclerosis (SPMS), according to a ... Read more

October 17, 2018October 22, 2018

#ECTRIMS2018 – Stem Cell Transplant Effectively Lessens Disability in Patients with Aggressive MS, Study Finds

News

Treatment with autologous hematopoietic stem cell transplant (aHSCT) led to a safe and rapid lessening of disability and no clinical relapses in patients with aggressive multiple ... Read more

October 16, 2018October 16, 2018

#ECTRIMS2018 – Evobrutinib and Other Reasons for Hope in Pursuit of MS Treatments, Jerry Wolinsky Says in Interview

News

Advances in multiple sclerosis research and the development of new treatments over the last several decades give sustained reasons for hope as continue moving toward our future, ... Read more

October 16, 2018October 22, 2018

#ECTRIMS2018 – Two European Studies Compare Tecfidera, Aubagio Effectiveness

News

Treatment of relapsing-remitting multiple sclerosis (RRMS) patients with Tecfidera (dimethyl fumarate) is associated with fewer new brain lesions at two years, lower relapse rates, increased time to ... Read more

October 16, 2018November 27, 2018

#ECTRIMS2018 – Study Examines Relapses When Stopping Gilenya During, After Pregnancy

News

Up to half of women with multiple sclerosis (MS) who stop treatment with Gilenya (fingolimod) when planning to become pregnant will experience a relapse during pregnancy, ... Read more

October 15, 2018October 15, 2018

#ECTRIMS2018 – Plasma Neurofilament Light Levels Linked to Treatment Effects in RRMS, Study Finds

News

Levels of proposed biomarker neurofilament light chain (NfL) are associated with therapeutic effects of disease-modifying treatments (DMTs) in relapsing-remitting multiple sclerosis (RRMS) patients, according to a real-world study. ... Read more

October 12, 2018October 12, 2018

#ECTRIMS2018: Study Proposes Serum Neurofilament Light Threshold to Identify RRMS Patients at Risk of Worsening

News

Relapsing-remitting multiple sclerosis (RRMS) patients with serum neurofilament light chain (sNfL) levels higher than a proposed threshold have a higher risk of disease activity, and worsened ... Read more

October 12, 2018October 12, 2018

#ECTRIMS2018 — In CIS Patients, Early Lesions in Specific Brain Area Linked to Worse Disability 30 Years Later, Study Shows

News

Lesions in the infratentorial region of the brain at the onset of clinically isolated syndrome (CIS) and lesions in white matter one year after CIS onset are ... Read more

October 12, 2018October 12, 2018

#ECTRIMS2018 — Early Relapses and Larger Lesions Increase Risk of Developing SPMS, Study Reports

News

A higher frequency of early relapses, as well as a larger volume of lesions and older age at disease onset, increase the risk of transitioning from ... Read more

October 11, 2018October 17, 2018

#ECTRIMS2018 — Infections, Severe Disability Complications More Likely Causes of Death in MS Patients, Study Shows

News

Infections and complications from severe disability are the greatest contributors to mortality among multiple sclerosis (MS) patients, according to a population-based study in British Columbia, Canada, which ... Read more

October 11, 2018October 11, 2018

#ECTRIMS2018 – Brain, Spinal Cord Injuries Affect Processing Speed in MS Patients, Study Reveals

News

Processing speed is associated with the extent of brain and spinal cord injury in patients with multiple sclerosis (MS), according to a new study conducted in ... Read more

October 11, 2018October 11, 2018

#ECTRIMS2018 – Rituximab for MS Does Not Increase Cancer Risk Compared to Gilenya and Tysabri, Swedish Study Finds

News

Treatment of multiple sclerosis (MS) patients with rituximab does not increase breast cancer risk in women, and is not associated with a higher risk for malignant ... Read more

October 11, 2018October 11, 2018

#ECTRIMS2018 – Lower Mortality Rate in US, Sweden for MS Patients Treated With Rituximab, Study Reports

News

Treatment of multiple sclerosis (MS) patients with rituximab leads to lower-than-reported mortality rates, according to a large real-world study in the U.S. and Sweden. The findings ... Read more

October 10, 2018October 17, 2018

#ECTRIMS2018 — Vitamin D May Boost Glucocorticosteroid Effectiveness in MS Relapses, Study Suggests

News

Vitamin D may increase the therapeutic benefits of glucocorticosteroids (GCs) for multiple sclerosis (MS) through a protein complex called mTORc1, according to a study in a mouse ... Read more

October 10, 2018October 10, 2018

#ECTRIMS2018 – Switching to Tysabri Leads to Fewer Relapses and Disability than Gilenya, Study in RRMS Patients Finds

News

Patients with relapsing-remitting multiple sclerosis (RRMS) who switch to Tysabri (natalizumab) after relapses on first-line treatment with other medications show greater relapse reduction and less disability ... Read more

October 10, 2018October 15, 2018

#ECTRIMS2018 – Researcher Presents Data About Myelocortical MS, a New Disease Subtype

News

A new subtype of multiple sclerosis (MS) — called myelocortical MS (MCMS) — is characterized by cortical neuronal loss, but not by loss of myelin in ... Read more

October 5, 2018October 11, 2018

#ECTRIMS2018 — Biogen’s MS Treatments Found Safe, Effective in Clinical and Real-world Data

News

Clinical data and real-world results support the long-term efficacy of Biogen’s medications for multiple sclerosis (MS), according to scientific presentations being released by the company. Specifically, ... Read more

October 4, 2018October 11, 2018

#ECTRIMS2018 – Genentech to Present Ocrevus-related MS Studies at Conference

News

Treatment with Ocrevus (ocrelizumab) over five years lessened upper limb disability progression in primary progressive multiple sclerosis (PPMS) patients, reduced relapses and brain disease activity in ... Read more

September 28, 2018October 8, 2018

#ECTRIMS2018 – Ublituximab Markedly Reduces Lesions, Promotes B-cell Depletion, Halts Disability Progression in Phase 2 Trial

News

A 48-week treatment of relapsing multiple sclerosis (MS) with TG Therapeutics’ investigational compound ublituximab led to a marked reduction of brain and spinal cord lesions, massive ... Read more

Pin It on Pinterest